EDAP announces a collaboration with Inserm and Epitarget AS on a Research Program for Cancer Treatment
The global leader in therapeutic ultrasound EDAP, has announced a cooperation with the Norwegian therapeutics company Epitarget AS, and INSERM, the French public organization dedicated to biological, medical and public health research.
They are going to collaborate on a program to improve delivery of cancer drugs, using a combination of ultrasound sensitive liposomes and therapeutic ultrasound (EDAP’s HIFU).
The project obtained public funding
The project, which obtained the EUREKA status (a European quality label and prerequisite for obtaining French public support on industrial project), has been awarded a public grant via:
 | the French Norwegian Foundation,
|
| the French Ministry of Research, and
|
| the French Innovation Society. |
Entitled, "Novel Sonosensitive Liposomes and Systems for Targeted Ultrasound Mediated Drug Delivery", the project aims at developing an application using EDAP’s HIFU technology to precisely deliver drugs encapsulated within liposomes to deep seated tumors while facilitating drug absorption by the cancerous cells.
Further info
Website: www.edap-hifu.com
